Menu

More Retractions for Cancer Researcher

An institutional investigation has found evidence of image manipulation in two studies coauthored by Bharat Aggarwal.

Jun 22, 2016
Tanya Lewis

Flavopiridol, the subject of the retracted 2008 Molecular Pharmacology paperWIKIMEDIA, JAGAFollowing an investigation by his former employer, MD Anderson Cancer Center, Molecular Pharmacology has retracted two papers coauthored by Bharat Aggarwal, citing “inappropriate” or “unacceptable” image manipulation, Retraction Watch reported yesterday (June 21).

The studies in question—a 2008 paper on how a semisynthetic flavone mediates antitumor responses, and a 2011 paper about a novel potential cancer drug—were cited 27 and five times, respectively, according to Thomson Reuters Web of Science.

“MD Anderson Cancer Center is committed to the highest standards of scientific integrity,” the institution noted in a statement sent to Retraction Watch. “Any scientific work that does not adhere to the highest standards of scientific integrity is not acceptable.”

The latest retractions follow on seven other retractions of papers coauthored by Aggarwal. All seven papers contained figures that were reused or manipulated, according to their associated retraction notices. Aggarwal has also amassed six corrections, two unexplained withdrawals, and two expressions of concern, according to Retraction Watch, a website the cancer researcher previously threatened to sue.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.